←
Erasca20 posts
Erasca avatar

Erasca

@Erasca

Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer by shutting down one of cancer's most commonly mutated pathways.

◷ Joined July 2021▧ 9 Photos and videos
Erasca avatar
Erasca@Erasca·14h

We’re pleased to announce that we entered into a clinical collaboration with @bmsnews to evaluate the combination of ERAS-0015 and navlimetostat, an investigational PRMT5 inhibitor, in patients with MTAP-deleted pancreatic cancer. Learn more: investors.erasca.com/news-re…

0:19
Erasca avatar
Erasca@Erasca·Nov 16

Following #ENA2026 in Barcelona, Erasca will host a virtual investor event on November 20 at 8:00 a.m. ET, highlighting clinical momentum across our RAS-targeting franchise. To register and learn more, visit: bit.ly/4iMRfqk

Post attachment
Erasca avatar
Erasca@Erasca·Nov 13

Check out our Q3 2026 results and corporate updates, which highlight continued momentum across our pipeline as we advance toward our goal of developing treatments for #pancreatic and #lung cancers. More: bit.ly/4sXSkAx

0:13
Erasca avatar
Erasca@Erasca·Nov 6

Erasca has won the @BioTech_Awards 2026 R&D Platform of the Year award! Thank you to our team, researchers, clinicians, patients and partners for helping advance our mission to erase cancer Learn more about our work: bit.ly/4BF5oii

Post attachment
Erasca avatar
Erasca@Erasca·Oct 29

Little Erascals, BIG Halloween spirit! 🎃 Our team and their families celebrated with costumes, trick-or-treating, snacks, and crafts. Here’s a peek at the fun! #TeamErasca #HappyHalloween

Post attachmentPost attachmentPost attachmentPost attachment
Erasca avatar
Erasca@Erasca·Jun 24

RAS mutations drive ~30% of all cancers. Thank you, @stephaniesirota, for the opportunity to discuss Erasca’s journey and our commitment to advancing therapies for patients with RAS/MAPK-driven cancers. #ASCO2026

In our #ASCO2026 coffee break miniseries, RTW CBO @stephaniesirota chatted with Dr. Shannon Morris, Chief Medical Officer of @Erasca. Dr. Morris shared the story behind Erasca's name and what it took to pursue a corner of oncology that was historically considered undruggable. The mic drop moment is when Dr. Morris shares that RAS mutations drive 30% of all tumor types.

1:54